+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

DURECT Corp (DRRX) - Financial and Strategic SWOT Analysis Review

DURECT Corp (DRRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

DURECT Corp (Durect) is a biopharmaceutical company that focuses on the research and development of new chemical entities for the treatment of acute organ injury and chronic liver diseases based on its endogenous epigenetic regulator program. The company's major product pipeline comprises DUR-928, indicated for the treatment of alcoholic hepatitis and nonalcoholic steatohepatitis (NASH); Posimir, indicated to treat post-operative pain; and Oradur, indicated for chronic pain and attention deficit hyperactivity disorders. Durect also manufactures and sells osmotic pumps for laboratory research; and offers standard and custom biodegradable polymers and excipients for customers in pharmaceutical and medical device industry. The company operates in the US, Europe, Japan and other countries. Durect is headquartered in Cupertino, California, the US.

DURECT Corp Key Recent Developments

  • May 08, 2023: DURECT reports Q1 2023 financial results and business update
  • Mar 21, 2023: DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board
  • Mar 07, 2023: DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update
  • Feb 28, 2023: DURECT to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • DURECT Corp - Key Facts
  • DURECT Corp - Key Employees
  • DURECT Corp - Key Employee Biographies
  • DURECT Corp - Major Products and Services
  • DURECT Corp - History
  • DURECT Corp - Company Statement
  • DURECT Corp - Locations And Subsidiaries
  • Head Office
Section 2 - Company Analysis
  • Company Overview
  • DURECT Corp - Business Description
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: Other
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • DURECT Corp - Corporate Strategy
  • DURECT Corp - SWOT Analysis
  • SWOT Analysis - Overview
  • DURECT Corp - Strengths
  • DURECT Corp - Weaknesses
  • DURECT Corp - Opportunities
  • DURECT Corp - Threats
  • DURECT Corp - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • DURECT Corp, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • DURECT Corp, Medical Equipment, Deals By Type, 2017 to YTD 2023
  • DURECT Corp, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 08, 2023: DURECT reports Q1 2023 financial results and business update
  • Mar 21, 2023: DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board
  • Mar 07, 2023: DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update
  • Feb 28, 2023: DURECT to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7
  • Nov 02, 2022: DURECT Corp Reports Third Quarter 2022 Financial Results and Update of Programs
  • Aug 04, 2022: DURECT Reports Second Quarter 2022 Financial Results and Update of Programs
  • Jul 05, 2022: DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer
  • May 18, 2022: DURECT Corp to Present at the H.C. Wainwright Global Investment Conference
  • May 04, 2022: DURECT Reports First Quarter 2022 Financial Results and Update of Programs
  • Mar 23, 2022: DURECT Corp. to Present at the 2022 Cantor Fitzgerald Virtual Rare Orphan Disease Summit
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • DURECT Corp, Key Facts
  • DURECT Corp, Key Employees
  • DURECT Corp, Key Employee Biographies
  • DURECT Corp, Major Products and Services
  • DURECT Corp, History
  • DURECT Corp, Key Competitors
  • DURECT Corp, Ratios based on current share price
  • DURECT Corp, Annual Ratios
  • DURECT Corp, Interim Ratios
  • DURECT Corp, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • DURECT Corp, Medical Equipment, Deals By Type, 2017 to YTD 2023
  • DURECT Corp, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • DURECT Corp, Performance Chart (2018 - 2022)
  • DURECT Corp, Ratio Charts
  • DURECT Corp, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • DURECT Corp, Medical Equipment, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AstraZeneca Plc
  • Medtronic Plc
  • Mallinckrodt Plc
  • Eli Lilly and Co
  • Immune Pharmaceuticals Inc
  • Cumberland Pharmaceuticals Inc
  • Pacira BioSciences Inc
  • Knoll Inc
  • AbbVie Inc
  • Purdue Pharma LP
  • Acorda Therapeutics Inc
  • Avadel Pharmaceuticals Plc